Transposon-Based TP53 Gene Therapy Using Lipid Nanoparticles ID: 2025-009
An innovative gene therapy approach to treat cancer by restoring the function of the TP53 gene, using a transposon system delivered via lipid nanoparticles.
Photo by starlineart - stock.adobe.com
Technology Overview
This technology utilizes a transposon-based system to deliver TP53 cDNA into the genome, aiming to restore the tumor-suppressing function of the TP53 gene. The delivery mechanism involves lipid nanoparticles (LNPs) optimized for cellular uptake and efficacy, incorporating a transposase enzyme for stable gene integration, and a dual approach to both enhance TP53 expression and suppress mutant TP53 alleles.
Key Advantages
- Stable expression of the P53 protein, activating apoptosis in cancer cells
- Optimized LNP formulation for efficient gene delivery and cellular uptake
- Targeted delivery to cancer cells, minimizing impact on healthy cells
- Suppression of mutant TP53 alleles, enhancing therapy specificity
Problems Addressed
- Uncontrolled proliferation of cancer cells due to TP53 gene mutations
- Limited efficacy and safety concerns of current cancer gene therapies
- Challenges in targeted delivery and stable expression of therapeutic genes
Additional Information
Technology ID: 2025-009
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025
Connect with the Tech Transfer to:
- Meet with the technology manager
- Receive additional information
- Request a marketing plan report